MGF (Mechano Growth Factor)
IGF-1Ec splice variant · PEG-MGF
IGF-1 splice variant expressed in muscle after loading; evidence is limited to cell and animal studies.
Not FDA-approved. Not approved. WADA-prohibited. This page describes research and public discussion; it is not a recommendation to use.
Overview
MGF is produced by muscle in response to mechanical stress and is thought to activate satellite cells. Synthetic MGF peptides sold for injection have never been tested in human trials.
Mechanism of action
The E-domain peptide is proposed to activate muscle satellite cells independently of the IGF-1 receptor.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Clinically studied dose C Preliminary research | None established | — | — | — |
Online / clinic protocols D Anecdotal / community Not derived from controlled human trials. Reported for transparency, not recommendation. | 100–200 mcg | Post-workout | Weeks | Intramuscular/subcutaneous |
Clinical trials & studies
- ReviewVariousMechano growth factor: review of physiology
Preclinical mechanisms; conflicting replication.
Safety
Side effects
- Unknown; theoretical hypoglycemia and growth-factor risks
Contraindications
- Cancer history
- Pregnancy
- Competitive sport
Interactions
- Insulin
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Not approved. WADA-prohibited.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.